DCPH News and Press, Deciphera Pharmaceuticals Inc. From 12/21/21

Deciphera Pharmaceuticals (NASDAQ:DCPH) perks up 3.7% premarket following an announcement that the U.K.'s Medicines and Healthcare products Regulatory Agency has granted marketing authorization for Qinlock (ripretinib) for the treatment of adult patients with advanced gastroint...

– QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company de...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deciphera Pharmaceuticals (NASDAQ: DCPH ) stock absolutely imploded in November. Shares lost more than two-thirds of their value virtually overnight. Source: Iryna Imago / Shutterstock.com DCPH stock plunged aft...

On a bad day for the stock market overall, Deciphera Pharmaceuticals (NASDAQ: DCPH) was quite the happy standout. Shares of the biotech closed more than 12% higher on Tuesday thanks to the launch of a new company initiative. Deciphera is in restructuring mode, with the aim being...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deciphera Pharmaceuticals  (NASDAQ: DCPH ) is a biotech company that develops drugs mainly for the treatment of cancer. Right now, DCPH stock shares are down nearly 85% year-to-date (YTD), at $7.70 as of the close...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sometimes, a big sell off can also be a big opportunity. But that’s not the case here with biotech play Deciphera  Pharmaceuticals  (NASDAQ: DCPH ). On Nov. 5, DCPH stock took a sudden plunge of more ...

Deciphera Pharmaceuticals (DCPH +7.9%) is undertaking a corporate restructuring and reducing its workforce by ~35%, to prioritize clinical development of select programs, streamline commercial operations and extend its cash runway. The company will focus its resources on the continued ad...

Deciphera Pharmaceuticals (NASDAQ:DCPH) will undergo a corporate restructuring that will result in the elimination of 35% of its workforce and the ending a phase 1/2 program for solid tumors. The company said it will focus resources on two candidates, vemseltinib and DCC-3116. The former is i...

– Resources Focused on the Clinical Development of Vimseltinib and DCC-3116; Rebastinib Program Discontinued – – US Commercial Operations Streamlined and Launches Planned in Select European Markets for QINLOCK ® – – Workf...

Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their flagship drug will not be moving from later-line to second-line therapy for GIST. With b...